TCGA-EW-A1PB-01A-11R-A144-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 20
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.710
- INTERFERON_GAMMA_RESPONSE+0.650
- ALLOGRAFT_REJECTION+0.580
- IL6_JAK_STAT3_SIGNALING+0.530
- INFLAMMATORY_RESPONSE+0.460
- MYC_TARGETS_V2+0.420
- COMPLEMENT+0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- UV_RESPONSE_UP+0.290
- MTORC1_SIGNALING+0.270
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- PROTEIN_SECRETION-0.400
- HEDGEHOG_SIGNALING-0.360
- TGF_BETA_SIGNALING-0.360
- UV_RESPONSE_DN-0.350
- ANDROGEN_RESPONSE-0.290
- ESTROGEN_RESPONSE_EARLY-0.230
- MITOTIC_SPINDLE-0.190
- MYOGENESIS-0.180
- ANGIOGENESIS-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | fe1628d5-92d9-4e5c-a441-531b699014f1 | — | — | 0.871 |
| 2 | TCGA-BH-A0C0-01A-21R-A056-07 | — | C | 0.870 |
| 3 | 20080305.TNBC | — | D | 0.870 |
| 4 | SRR35579807 | — | C | 0.869 |
| 5 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.864 |
| 6 | TCGA-4Z-AA7W-01A-11R-A39I-07 | — | — | 0.860 |
| 7 | TCGA-LL-A5YO-01A-21R-A28M-07 | — | D | 0.855 |
| 8 | 20100231.Her2HRpos | — | C | 0.852 |
| 9 | SRR8392897 | — | cohortSQ2 | 0.849 |
| 10 | TCGA-C8-A12K-01A-21R-A115-07 | — | E | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.710 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.650 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.290 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |